Skip to main content

Table 1 Patient characteristics

From: Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT

  DME nAMD
N 78 156
Age in years at inclusion | mean (SD) 63.5 (11.7) 78.2 (8.3)
Female gender | n (%) 30 (38.5) 95 (60.9)
Newly treated patients | n (%) 25 (32.1) 53 (34.0)
Experienced patients | n (%) 50 (64.1) 99 (63.4)
Non-persistent patients | n (%) 3 (3.8) 4 (2.6)
Time since first diagnosis of DME/nAMD in years | mean (SD) 3.0 (3.1) 2.9 (3.1)
Both eyes affected | n (%) 49 (62.8) 52 (33.3)
VA LogMAR at start of treatment—treated eye | mean (SD)a 0.5 (0.2) 0.4 (0.2)
VA LogMAR at start of treatment—untreated eye | mean (SD)b 0.5 (0.4) 0.5 (0.3)
Duration of treatment in years | mean (SD) 1.9 (0.8) 1.9 (0.9)
Duration of treatment ≤ 12 months | n (%) 14 (17.9) 32 (20.5)
Number of injections per treated eye since start of therapy | mean (SD) 8.9 (5.5)c 12.2 (9.0)d
Catarakt | n (%) 40 (51.3) 53 (34.0)
Glaucoma | n (%) 8 (10.3) 19 (12.2)
Diabetic Retinopathy | n (%) 63 (80.8) 0 (0.0)
Patient reading capabilities assessed by physicianse
Without magnifying glass | n (%) 39 (50%) 110 (70.5%)
With magnifying glass | n (%) 4 (5.1%) 16 (10.3%)
Not able to read | n (%) 0 (0%) 7 (4.5%)
Unknown | n (%) 35 (44.9%) 23 (14.7%)
Patient reading capabilities assessed by patientsc
Without magnifying glass | n (%) 59 (75.6%) 104 (66.7%)
With magnifying glass | n (%) 12 (15.4%) 40 (25.6%)
Not able to read | n (%) 7 (9%) 12 (7.7%)
Unknown | n (%) 0 (0%) 0 (0%)
  1. an = 325 eyes; bn = 141 eyes; cn = 125 eyes; dn = 202 eyes; eAt the time of study inclusion/phone interview; SD, standard deviation; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; VA, visual acuity; IVT, intravitreal anti-VEGF therapy